Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Erectile Dysfunction Among Testicular Cancer Survivors: A Systematic Review and Meta-Analysis, 2020

View through CrossRef
Abstract Background: Erectile dysfunction is one of the common complications of testicular cancer with the prevalence of 11.3% to 84%. It has devastating effects on men and partner’s quality of life, sexual satisfaction, and sexual experience. The findings of the previous studies on this matter were uneven and inconsistent. Therefore, this systematic review and meta-analysis is conducted in order to acquire a more recent and comprehensive result. Methods and materials: PubMed, Scopus, Goggle scholar, Science Direct, African Index Medicus, African Journal online, EMBASE, and Cochrane Library databases were searched. All necessary data were extracted using a standardized data extraction format. Data were analyzed using STATA 14 statistical software. A heterogeneity of studies was assessed using the I 2 statistics. Publication bias was checked by using a funnel plot and Egger's regression test. A random-effect model was computed to estimate the pooled prevalence of erectile dysfunction. Result: Fourteen full-text studies were included in this systematic review and meta-analysis. The pooled prevalence of erectile dysfunction among testicular cancer survivors was found to be 34.60% (95% CI: 25. 89, 43.30% [I 2 = 95.9%, p = 0.000]). Study design subgroup analysis indicated that the pooled prevalence of erectile dysfunction was 50.02% (95% CI: 22.78, 77.28% [I 2 = 96.1, p = 0.000]) and 27.36. % (95% CI: 19.23, 34.48% [I 2 = 91.6, P = 0.000]) in the case control and cohort studies respectively. Likewise, the level of erectile dysfunction was varied based on erectile dysfunction measuring tools and testicular cancer treatment modalities. Conclusion: The pooled prevalence of erectile dysfunction in testicular cancer survivors was found to be high. It had also a considerable discrepancy between the study designs, and measuring 3 tools and treatment modalities of testicular cancer. Therefore, there is a sound to diminish the high burden of this problem.
Title: Erectile Dysfunction Among Testicular Cancer Survivors: A Systematic Review and Meta-Analysis, 2020
Description:
Abstract Background: Erectile dysfunction is one of the common complications of testicular cancer with the prevalence of 11.
3% to 84%.
It has devastating effects on men and partner’s quality of life, sexual satisfaction, and sexual experience.
The findings of the previous studies on this matter were uneven and inconsistent.
Therefore, this systematic review and meta-analysis is conducted in order to acquire a more recent and comprehensive result.
Methods and materials: PubMed, Scopus, Goggle scholar, Science Direct, African Index Medicus, African Journal online, EMBASE, and Cochrane Library databases were searched.
All necessary data were extracted using a standardized data extraction format.
Data were analyzed using STATA 14 statistical software.
A heterogeneity of studies was assessed using the I 2 statistics.
Publication bias was checked by using a funnel plot and Egger's regression test.
A random-effect model was computed to estimate the pooled prevalence of erectile dysfunction.
Result: Fourteen full-text studies were included in this systematic review and meta-analysis.
The pooled prevalence of erectile dysfunction among testicular cancer survivors was found to be 34.
60% (95% CI: 25.
89, 43.
30% [I 2 = 95.
9%, p = 0.
000]).
Study design subgroup analysis indicated that the pooled prevalence of erectile dysfunction was 50.
02% (95% CI: 22.
78, 77.
28% [I 2 = 96.
1, p = 0.
000]) and 27.
36.
% (95% CI: 19.
23, 34.
48% [I 2 = 91.
6, P = 0.
000]) in the case control and cohort studies respectively.
Likewise, the level of erectile dysfunction was varied based on erectile dysfunction measuring tools and testicular cancer treatment modalities.
Conclusion: The pooled prevalence of erectile dysfunction in testicular cancer survivors was found to be high.
It had also a considerable discrepancy between the study designs, and measuring 3 tools and treatment modalities of testicular cancer.
Therefore, there is a sound to diminish the high burden of this problem.

Related Results

Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Unraveling the intersection of sleep disorders and erectile dysfunction: Outcomes from two EPISONO editions
Unraveling the intersection of sleep disorders and erectile dysfunction: Outcomes from two EPISONO editions
AbstractBackgroundThere is growing interest in the relationship between sleep disorders and erectile dysfunction. We present the results from a 2015 follow‐up study in relation to ...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

Back to Top